Findings

What do systematic reviews say?

841 questions · 868 findings · 102 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 276 · 31.8%GRADE not reported 111 · 12.8%Very low 197 · 22.7%Low 187 · 21.5%Moderate 88 · 10.1%High 9 · 1%

Hypnotics vs inactive control

AHI · adults with primary central sleep apnoea

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 5 participants
GRADE not reported

Hypnotics vs inactive control

All‐cause mortality · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Serious adverse events · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Quality of sleep · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Quality of life · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

AHI · adults with central sleep apnoea associated with heart failure

2 findings from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low
Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 18 participants
Very low

Carbonic anhydrase inhibitors vs inactive control

All‐cause mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

cAHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Radical prostatectomy vs active monitoring

Time to disease progressionMedian · clinically localized prostate cancer

Radical prostatectomy probably leads to lower time to disease progressionMedian compared with active monitoring (moderate certainty).

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
HR 0.39 [0.27, 0.56]
1 study · 1098 participants
Moderate

Radical prostatectomy vs active monitoring

Incidence of metastatic diseaseMedian · clinically localized prostate cancer

Radical prostatectomy probably leads to lower incidence of metastatic diseaseMedian compared with active monitoring (moderate certainty).

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
RR 0.39 [0.21, 0.73]
1 study · 1098 participants
Moderate

Radical prostatectomy vs active monitoring

Health‐related quality of life · clinically localized prostate cancer

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 856 participants
Moderate

Radical prostatectomy vs active monitoring

Urinary function · clinically localized prostate cancer

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 782 participants
Low

Radical prostatectomy vs active monitoring

Effect on later sexual function · clinically localized prostate cancer

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 756 participants
Low

Radical prostatectomy vs active monitoring

Time to death from any causeMedian · clinically localized prostate cancer

Radical prostatectomy showed no clear difference in time to death from any causeMedian compared with active monitoring (moderate certainty).

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
HR 0.93 [0.65, 1.33]
1 study · 1098 participants
Moderate

Radical prostatectomy vs active monitoring

Time to death from prostate cancerMedian · clinically localized prostate cancer

Radical prostatectomy showed no clear difference in time to death from prostate cancerMedian compared with active monitoring (moderate certainty).

1 finding from 1 review

Radical prostatectomy versus deferred treatment for localised prostate cancer 2020 · Cochrane Headline outcomes only
HR 0.63 [0.21, 1.89]
1 study · 1098 participants
Moderate

Rutosides vs an alternative venoactive remedy (hidrosmina)

Improvement in PTS · patients with PTS

Rutosides may leads to lower improvement in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).

1 finding from 1 review

Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
OR 0.18 [0.04, 0.94]
1 study · 29 participants
Low

Rutosides vs an alternative venoactive remedy (hidrosmina)

Deterioration in PTS · patients with PTS

Rutosides showed no clear difference in deterioration in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).

1 finding from 1 review

Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
OR 0.19 [0.01, 4.24]
1 study · 29 participants
Low

Rutosides vs an alternative venoactive remedy (hidrosmina)

Adverse effects · patients with PTS

The review found no eligible studies for this question.

1 finding from 1 review

Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rutosides vs an alternative venoactive remedy (hidrosmina)

Occurrence of leg ulceration · patients with PTS

The review found no eligible studies for this question.

1 finding from 1 review

Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.77 [0.39, 1.53]
4 studies · 1055 participants
Low